Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Apr 26, 2024

New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
Mar 8, 2024

New data presented at AAD showcase continued commitment to advance treatments for inflammatory dermatologic diseases
Feb 24, 2024

Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
Feb 23, 2024

Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Feb 9, 2024

New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases
Feb 5, 2024

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Feb 1, 2024

Sanofi launches Beyfortus® (nirsevimab-alip) Reservation Program for 2024-2025 RSV season in U.S.
Jan 25, 2024

Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Jan 16, 2024

Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement
Dec 14, 2023

Sanofi Beyfortus™ (nirsevimab-alip) Injection Update

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.